Paracetamol 325 mg Camylofin 50 mg Tablets are a fixed dose pharmaceutical combination in the form of a solid oral dosage form: a tablet. The formulation for the tablets comprises the drug substance Paracetamol 325 mg, the drug substance Camylofin 50 mg and suitable pharmaceutical excipients to ensure uniform characteristics and quality of production.
Formulation Considerations for a combination tablet include the characterization of the individual physicochemical properties of both active ingredients and the compatibility of the two in a combined dosage form. Other factors that must be taken into account are particle size, powder flow, bulk density, compressibility, compatibility, blend uniformity, and stability of the finished-tablet dosage form.
Product can be in the range of diversified pharmaceutical portfolio with combination tablets and other forms of administration form. For pharmaceutical companies looking for the PCD Pharma Franchise range, professionally manufactured formulations with uniform composition, quality testing and pack may help to build a product portfolio.
4.2 Posology and method of administration Each dosage form consists of the active ingredients, Paracetamol 325 mg, as the first active ingredient and 50 mg, as the second active ingredient. The Particle properties and flow behavior of the ingredients may not be the same and hence pre-formulation study is required during formulation development.
The paracetamol is added at the required strength of 325 mg and it can significantly affect the properties of the powder mix and compression. You could test the particle size, flow properties and the ability of it to the excipients used.
Camylofin 50 mg is placed in accordance with approved formulation specification. Controlled dispensing and uniform mixing is essential for satisfactory distribution throughout the batch.
The pharmaceutical excipients can be compliant diluents, binders, disintegrants, lubricants, glidants, or other functional materials. The pharmaceutical excipients are opted according to its intended technological role, relevant compatibility and contribution to the final tablet properties.
Pre-formulation studies are useful in identifying the suitable excipient system and manufacturing process. Compatibility testing is important in the case of combination products where the active drug substance(s) and excipients should stay within the required physical and chemical characteristics throughout processing and storage.
Materials are receipted, sampled, identified and tested before use during the manufacture of this medicine and only those complying with the required specification are permitted for release. Raw Material Release for Composition of Paracetamol 325 mg with Camylofin 50 mg Tablets.
Correct dispensing of active substances and excipients shall be made in accordance with the batch manufacturing formula approved. Formulation technology will determine manufacturing process comprising sifting, pre-blending, granulation, drying, milling, lubrication and compression, as the case may be.
Factor 2: Uniformity of the blend Uniformity of the blend must be taken into account since two active ingredients are incorporated into a final powder blend. Mixing time, amount of equipment load, order of addition and other process variables can be defined in the formulation development.
A further decision can be made as to whether the dosage form is manufactured by direct compression or by a granulation based process, depending on the physical properties of the components. The technology chosen should enable the compression profile to be achieved with acceptable content uniformity.
In-process controls include monitoring of tablet compression parameters such as compression force, machine speed, weight, thickness, hardness and visual appearance. If film coating is part of the approved formulation, the parameters are controlled during coating to ensure coverage and appearance.
3. Quality Control QC of Paracetamol 325 mg with Camylofin 50 mg Tablets The final tablets may be subjected to physical, chemical, and performance tests in accordance with specifications.
Assessment of quality may consist of: Assay and Identification for Paracetamol and Camylofin. Uniformity of weight and dosage. Average weight, variation of weight, and hardness. Friability, thickness and disintegration, dissolution and sight.
As this is a two-active-ingredient formulation, appropriate analytical methods are required to enable the separation and measurement of each active ingredient individually. The analytical methods should be appropriately developed and validated for the specific formulation.
In-process testing is also possible during blending and compression. Blend uniformity testing can be used to assess the uniformity of the active drug, as can weight and dimension checks during compression.
Finished-product inspection may encompass visual inspection of chips, cracks, capping, lamination, staining, coating imperfections, or other visual irregularities when relevant.
Tracking and tracing evidence All the following information as supporting documentation can be used to put together a filing system of product traceability: raw-material records, dispensing forms, batch manufacturing records, in-process reports, analytical records, packaging records, and the final batch-release documentation.
Determine the stability of Paracetamol 325 mg with Camylofin 50 mg Tablets to determine its stability profile and to support quality during the shelflife. Stability studies can include physical appearance, assay, dissolution, disintegration, degradation state parameters and others, as appropriate, under specified conditions.
Package system is based on the formulation need for stability. Depending on the product specification, pharmaceutical-grade blister packs, blister strips, alu-alu packs, bottles or other appropriate packages may be used.
Packaging that is suitable for tablets ensures they are protected from extraneous environmental factors and physical damage during storage, transfer and transportation. Container-closure compatibility can be assessed in the development of the product.
For the commercial presentation, the controls on the packaging line would consist of a check of the number of tablets, correct filling, quality of the seals, quality of print, batch number and overall pack integrity.
Product Labeling: The labeling should be readable and should clearly state product name, composition, strength, batch information, manufacturing details, expiry details, pack size, storage details and other regulatory details, if any.
315 paracetamol and camylofin 5 mg Tablet may be part of a broad pharmaceutical product portfolio that includes combination tablets, single-source products, capsules, syrups, softgels and other formulations. Formulation of such an article would involve an integrated approach to raw-materials quality, formulation compatibility, blending properties, compression characteristics, analytical testing and stability.
For PCD Pharma Franchise companies, a broad and well-organized product range will help with professional product positioning. Overall portfolio credibility can be achieved with trusted sources, standard manufacturing procedures, quality-control tests, and packaging.
Contents are prepared from Raw Materials manufactured according to defined criteria and validated via Dispensing, Accurate Blending, Effective Tablet Compression, Finishing product testing, stability, and in the end, Packaging. Every step has its own purpose and importance in the manufacturing and testings of this dosage form.
For the stated formula: Paracetamol 325 mg + Camylofin 50 mg Tablet this formulation can be made by using the technique of quality manufacturing and consuming techniques, i.e.:- Ingredient uniformity, tablet physical strength, analytical precision, packaging protection, and stable quality, and covering in a batch by batch presentation.
We combine quality, innovation, and strong distribution to help our partners grow successfully in the pharma market.
The company is offering business opportunity for scalable and sustainable returns to its associates. We are engaged in discovery, development and commercialization of pharmaceutical medicine keeping in mind its quality and affordability.
© Novolilly 2025. All Rights Reserved – Developed & Managed By Kavir Infotech